Sciele: all $150 million of 1.75% notes converted ahead of redemption

By Susanna Moon

Chicago, June 15- Sciele Pharma, Inc. said all holders of the 1.75% contingent convertible subordinated notes due 2024 exercised their option to convert the notes into common stock.

The conversion ahead of redemption represented all $150 million of outstanding notes, which were converted into 839,399 shares of stock.

On June 14, the company completed the conversion.

Sciele is an Atlanta-based pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.